IntelGenx (TSXV:IGX; OTCQX:IGXT) updated its cannabis-infused VersaFilm product co-development program with Tilray (NASDAQ:TLRY), following recently proposed Government of Canada amendments to the Cannabis Act that would authorize the sale of edible cannabis products.
“We are pleased with the timeliness of the Canadian Government’s proposed amendments to the Act and we will be participating in the public consultation process,” Dr. Horst Zerbe, president and CEO of IntelGenx, said in a statement.
“In addition to having the only Health Canada licensed and GMP compliant facility for pharmaceutical oral film manufacturing, IntelGenx has the competitive advantage of having Tilray, a global leader in cannabis production and distribution, as both a partner and shareholder,” he added.
Under the the development and supply agreement that IntelGenx inked with Tilray in November 2018, the companies will co-develop and commercialize oral film products infused with adult-use and medical cannabis.
“Together, we will work to develop a cannabis-infused oral film that complies with the proposed, and subsequently, the final amendments to the Act such that we are ready for commercialization shortly after the October 17, 2019 implementation deadline,” Dr. Zerbe said, pointing to a launch in late-2019.
